





































Pharmaceuticals – Pipeline Übersicht¹ (Stand 6. November 2023)

Phase 0 ²	Phase I	Phase II	Phase III
PSMA SMOL TAC (BAY 3563254)  ●	AhR-Inhibitor (BAY 2416964)  ●	Regorafenib (combi Nivolumab) (BAY 734506)  ○	Darolutamide (AR-Inhibitor)  ○
VVD STAT3-Inh (BAY 3630914)  ●	mEGFR-Inhibitor (BAY 2927088)  ●	Asundexian (FXIa-Inhibitor) (BAY 2433334)  ●	Finerenone (MR-Antagonist)  ○
Nächste Generation Leber-MRT (BAY 3393081)  ●	DGKzeta-Inhibitor (BAY 2965501)  ●	Zabedoseritib (IRAK4-Inh.) (BAY 1834845)  ●	Vericiguat (sGC-Stimulator)  ○
	CCR8 Ab (BAY 3375968)  ●	Runcaciguat (sGC-Aktivator) (BAY 1101042)  ●	Asundexian (FXIa-Inhibitor)  ●
	VVD KEAP1 Akt (VVD-13307 aka NRF2 Inhibitor, BAY 3605349)  ●		Elinzanetant (Neurokinin-1,3 Rez.-Antagonist)  ●
	DGKalpha-Inh (BAY 2862789)  ●		Aflibercept 8MG (VEGF-Inhibitor)  ○
	PSMA TAC (BAY 3546828)  ●		Gadoquatrane (Kontrastmittel Hoher Relaxivität)  ●
	Herzinsuffizienz rAAV Gentherapie (AB-1002 aka NAN-101)  ●		
	sGC-Aktivator Oral (BAY 3283142)  ●		
	Anti-a2AP (BAY 3018250)  ●		
	SEMA 3a (BAY 3401016)  ●		
	Anti-Koagulant (BAY 3389934)  ●		
	Bemdaneprocel (Morbus Parkinson-Zelltherapie) (BRT-DA01)  ●		
	Morbus Parkinson rAAV Gentherapie (AB-1005 aka AAV2-GDNF-PD)  ●		
	Multiple Systematrophie rAAV Gentherapie (AB-1005 aka AAV2-GDNF-MSA)  ●		
	Morbus Pompe rAAV Gentherapie (ACTUS-101)  ●		
	Huntington-Krankheit rAAV Gentherapie (AB-1001 aka BV-101)  ●		
	LGMD2I/R9 rAAV Gentherapie (AB-1003 aka LION-101)  ●		
	GPR84-Antagonist (BAY 3178275)  ●		
	BAY 2701250  ●		

- Onkologie
- Herz-Kreislauf+⁴
- Neurologie & Seltene Erkrankungen
- Immunologie
- Andere

- Neue aktive Substanz
- Life cycle management

Einreichungen
Aflibercept 8MG (VEGF-Inhibitor)  ○
<ul style="list-style-type: none"> # EU, JP: Diabetisches Makulaödem (DME) # EU, JP, CN: Neovasc. Altersbed. Makuladegen. (nAMD)

-  Proteintherapeutika
-  Zelltherapie
-  Kontrastmittel
-  Genetische Medizin
-  Radiotherapie
-  Kleines Molekül

¹ Bayer und Partner gesponsorte Studien, sowie zulassungsrelevante Studien Dritter mit erstem Studienbesuch des ersten Patienten (m/w/d) ² Präklinische ausgewählte Programme auf dem Weg zur IND-Zulassung (Investigational New Drug Application, USA) ³ Durchgeführt von Merck & Co ⁴ Einschließlich Präzisions-Herz-Kreislauftherapien, Nephrologie & Akutversorgung